News

MorphoSys has received clearance from Germany’s Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees in Germany to commence a Phase 1b/2a human clinical trial in

ISTA Pharmaceuticals has presented additional results from Bepreve (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. Bepreve is a non-sedating, highly selective antagonist of the histamine (H1)

Bend Research has entered into a collaboration with Vertex Pharmaceuticals (Vertex). Through the collaboration, Vertex will utilise Bend’s formulation development and manufacturing services for specific projects and clinical

The US Department of Health and Human Services (HHS) has reported the contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat

The FDA has accepted ChemGenex Pharmaceuticals’ (ChemGenex) New Drug Application (NDA) for Omapro (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed

Ikano Therapeutics (ITI) has received Orphan Drug designation for midazolam in the acute treatment of certain forms of epileptic seizure. ITI has a nasally administered form of midazolam

Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical (Tianda). The company said that the acquisition

AnaSpec has enhanced its SensoLyte pNPP Alkaline Phosphatase Assay kits with the addition of a specially formulated pNPP substrate. According to AnaSpec the new substrate advantages include, ready

Compugen has reported the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes. The company said that the new biomarker was discovered